Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
Cuorvo LV, Verderio P, Ciniselli CM, Girlando S, Decarli N, Leonardi E, Ferro A, Caldara A, Triolo R, Eccher C, Cantaloni C, Mauri F, Seckl M, Volante M, Buttitta F, Marchetti A, Silvia Q, Galligioni E, Palma PD, Barbareschi M. Cuorvo LV, et al. Among authors: decarli n. Virchows Arch. 2014 Jan;464(1):85-93. doi: 10.1007/s00428-013-1500-7. Virchows Arch. 2014. PMID: 24233241
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
Barbareschi M, Cuorvo LV, Girlando S, Bragantini E, Eccher C, Leonardi E, Ferro A, Caldara A, Triolo R, Cantaloni C, Decarli N, Galligioni E, Dalla Palma P. Barbareschi M, et al. Among authors: decarli n. Virchows Arch. 2012 Aug;461(2):129-39. doi: 10.1007/s00428-012-1267-2. Epub 2012 Jun 29. Virchows Arch. 2012. PMID: 22744290
In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, Cantaloni C, Gasperetti F, Cazzolli D, Berlanda G, Bernardi D, Pellegrini M, Triolo R, Ferro A, Verderio P, Barbareschi M. Giuliani S, et al. Among authors: decarli n. Virchows Arch. 2016 Jul;469(1):45-50. doi: 10.1007/s00428-016-1940-y. Epub 2016 Apr 21. Virchows Arch. 2016. PMID: 27097809
Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.
Giuliani S, Leonardi E, Aldovini D, Bernardi D, Pellegrini M, Soli F, Ferro A, Dalla Palma P, Decarli N, Barbareschi M. Giuliani S, et al. Among authors: decarli n. Pathologica. 2012 Jun;104(3):93-7. Pathologica. 2012. PMID: 22931039
PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.
Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A. Michelucci A, et al. Among authors: decarli n. Diagn Mol Pathol. 2009 Dec;18(4):200-5. doi: 10.1097/PDM.0b013e31818e5fa4. Diagn Mol Pathol. 2009. PMID: 19861897
21 results